Stromal-derived factor 1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice.
暂无分享,去创建一个
Axel Benner | Peter Lichter | Lars Bullinger | Hartmut Döhner | Stephan Stilgenbauer | L. Bullinger | H. Döhner | P. Lichter | S. Stilgenbauer | A. Benner | J. Cashman | A. Kröber | Alexander Kröber | Till Seiler | Elsbeth Brückle | T. Seiler | Elsbeth Brückle | Axel Benner | C. Eaves | Ian Clark-Lewis | Allen Eaves
[1] Sunil J Rao,et al. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2003 .
[2] K. Do,et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. , 2001, Blood.
[3] A. Pettitt,et al. CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia. , 2001, Blood.
[4] R. Rosenquist,et al. CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. , 2001, Blood.
[5] A Benner,et al. Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.
[6] T J Hamblin,et al. Immunoglobulin V genes and CD38 expression in CLL. , 2000, Blood.
[7] K. Rajewsky,et al. Cellular origin of human B-cell lymphomas. , 1999, The New England journal of medicine.
[8] T J Hamblin,et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.
[9] N. Chiorazzi,et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.
[10] L. Rassenti,et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. , 1998, The Journal of clinical investigation.
[11] L. Kanz,et al. Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer. , 1998, Seminars in oncology.
[12] B. Cheson,et al. Chronic lymphocytic leukemia: staging and prognostic factors. , 1998, Seminars in oncology.
[13] P. Andersen,et al. In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis: a cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients. , 1997, Leukemia research.
[14] E. Montserrat,et al. Chronic lymphocytic leukemia. , 1995, The New England journal of medicine.
[15] A Benner,et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.
[16] I. Tomlinson,et al. The human immunoglobulin VH repertoire. , 1995, Immunology today.
[17] G. Dighiero,et al. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. , 1994, Immunology today.
[18] E. Newcomb,et al. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression , 1993 .
[19] Berthold Lausen,et al. Maximally selected rank statistics , 1992 .
[20] G. Gaidano,et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[21] E. Korn. Censoring distributions as a measure of follow-up in survival analysis. , 1986, Statistics in medicine.
[22] Mark J. Thomas,et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis , 1981, Cancer.
[23] D C Case,et al. Clinical staging of chronic lymphocytic leukemia. , 1977, The Journal of the Maine Medical Association.
[24] D. M. Weir,et al. Handbook of experimental immunology , 1967 .
[25] D.,et al. Regression Models and Life-Tables , 2022 .